Home » Vonvendi Launches in the U.S. Market
Vonvendi Launches in the U.S. Market
Shire has launched the first recombinant treatment for von Willebrand factor in the U.S.
The drug was approved in December after a pivotal study demonstrated that all participants reported successful treatment of bleeding episodes.
The company did not detail its release plans or price point for the drug. — Cynthia Jessup
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May